Elena Ribakovsky

1.2k total citations
16 papers, 211 citations indexed

About

Elena Ribakovsky is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Elena Ribakovsky has authored 16 papers receiving a total of 211 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pathology and Forensic Medicine, 7 papers in Oncology and 5 papers in Genetics. Recurrent topics in Elena Ribakovsky's work include Lymphoma Diagnosis and Treatment (9 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Acute Myeloid Leukemia Research (2 papers). Elena Ribakovsky is often cited by papers focused on Lymphoma Diagnosis and Treatment (9 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Acute Myeloid Leukemia Research (2 papers). Elena Ribakovsky collaborates with scholars based in Israel and Germany. Elena Ribakovsky's co-authors include Arnon Nagler, Abraham Avigdor, Katia Beider, Meirav Kedmi, Lola Weiss, Eithan Galun, Hanna Wald, Amnon Peled, Michal Abraham and Maya Koren‐Michowitz and has published in prestigious journals such as Blood, Clinical Cancer Research and Biology of Blood and Marrow Transplantation.

In The Last Decade

Elena Ribakovsky

16 papers receiving 209 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Elena Ribakovsky Israel	8	103	78	57	53	50	16	211
Luc Mathieu Fornecker France	7	168 1.6×	150 1.9×	58 1.0×	56 1.1×	100 2.0×	17	322
Jana Mihályová Czechia	7	136 1.3×	57 0.7×	90 1.6×	49 0.9×	71 1.4×	16	251
Esperanza Lavilla Spain	8	100 1.0×	49 0.6×	65 1.1×	36 0.7×	23 0.5×	12	200
Sadia Falcioni Italy	9	105 1.0×	75 1.0×	62 1.1×	52 1.0×	101 2.0×	13	260
Toshie Ogasawara Japan	8	73 0.7×	46 0.6×	114 2.0×	59 1.1×	47 0.9×	25	280
Petr Kosztyu Czechia	10	124 1.2×	32 0.4×	94 1.6×	43 0.8×	46 0.9×	23	286
Sathej Gopalakrishnan United States	9	74 0.7×	49 0.6×	48 0.8×	72 1.4×	38 0.8×	22	220
Eugene Nikitin Russia	8	48 0.5×	76 1.0×	134 2.4×	118 2.2×	50 1.0×	62	301
Fauzia Ullah United States	10	118 1.1×	39 0.5×	66 1.2×	18 0.3×	25 0.5×	26	210
Z. Shen China	4	124 1.2×	137 1.8×	139 2.4×	22 0.4×	67 1.3×	7	293

Countries citing papers authored by Elena Ribakovsky

Since Specialization

Citations

This map shows the geographic impact of Elena Ribakovsky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elena Ribakovsky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elena Ribakovsky more than expected).

Fields of papers citing papers by Elena Ribakovsky

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elena Ribakovsky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elena Ribakovsky. The network helps show where Elena Ribakovsky may publish in the future.

Co-authorship network of co-authors of Elena Ribakovsky

This figure shows the co-authorship network connecting the top 25 collaborators of Elena Ribakovsky. A scholar is included among the top collaborators of Elena Ribakovsky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elena Ribakovsky. Elena Ribakovsky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Benjamini, Ohad, Erez Bar‐Haim, Yaniv Lustig, et al.. (2022). Cellular and humoral response to the fourth BNT162b2 mRNA COVID‐19 vaccine dose in patients with CLL. European Journal Of Haematology. 110(1). 99–108. 9 indexed citations

Avigdor, Abraham, et al.. (2020). Progression of disease within 24 months of initial therapy (POD24) detected incidentally in imaging does not necessarily indicate worse outcome. Leukemia & lymphoma. 61(11). 2645–2651. 7 indexed citations

Shimony, Shai, Netanel A. Horowitz, Elena Ribakovsky, et al.. (2019). Romidepsin treatment for relapsed or refractory peripheral and cutaneous T‐cell lymphoma: Real‐life data from a national multicenter observational study. Hematological Oncology. 37(5). 569–577. 16 indexed citations

Avigdor, Abraham, et al.. (2019). Efficacy of Gemcitabine as Salvage Therapy for Relapsed and Refractory Aggressive Non-Hodgkin Lymphoma. Acta Haematologica. 141(2). 84–90. 8 indexed citations

Ribakovsky, Elena, et al.. (2019). Progression of Follicular Lymphoma within 24 Months of First Treatment (POD -24) As a Predictor of Overall Survival - a Single Center Retrospective Analysis. Blood. 134(Supplement_1). 1534–1534. 3 indexed citations

Ribakovsky, Elena, Abraham Avigdor, Vladimir Vainstein, et al.. (2019). Outcome of Relapsed DLBCL Patients, Treated with Polatuzumab-BR or Polatuzumab-R: Real Life Data. Blood. 134(Supplement_1). 5321–5321. 4 indexed citations

Beider, Katia, Avichai Shimoni, Merav Leiba, et al.. (2016). The Sphingosine-1-Phosphate Modulator FTY720 Targets Multiple Myeloma via the CXCR4/CXCL12 Pathway. Clinical Cancer Research. 23(7). 1733–1747. 33 indexed citations

Benjamini, Ohad, Elena Ribakovsky, Meirav Kedmi, et al.. (2016). Evaluation of the Risk of Hepatitis B Reactivation Among Patients with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors. Blood. 128(22). 5429–5429. 6 indexed citations

Gafter‐Gvili, Anat, Elena Ribakovsky, Abraham Avigdor, et al.. (2015). Infections associated with bendamustine containing regimens in hematological patients: a retrospective multi-center study. Leukemia & lymphoma. 57(1). 63–69. 23 indexed citations

10.

Kedmi, Meirav, Tima Davidson, Ginette Schiby, et al.. (2015). Prognostic Value of Interim and End of Treatment FDG-PET/CT Scan Results in Adult Patients with Burkitt Lymphoma - a Retrospective Analysis of a Single Center Cohort. Blood. 126(23). 5025–5025. 1 indexed citations

11.

Apel, Arie, Meirav Kedmi, Miriam Berkowicz, et al.. (2014). Outcome differences in patients with precursor B cell acute lymphocytic leukemia over time: a retrospective analysis.. PubMed. 16(4). 224–8. 1 indexed citations

12.

Kedmi, Meirav, Irit Avivi, Elena Ribakovsky, et al.. (2014). Is there a role for therapy response assessment with 2-[fluorine-18] fluoro-2-deoxy-d-glucose–positron emission tomography/computed tomography in mantle cell lymphoma?. Leukemia & lymphoma. 55(11). 2484–2489. 16 indexed citations

13.

Beider, Katia, Elena Ribakovsky, Michal Abraham, et al.. (2013). Targeting the CD20 and CXCR4 Pathways in Non-Hodgkin Lymphoma with Rituximab and High-Affinity CXCR4 Antagonist BKT140. Clinical Cancer Research. 19(13). 3495–3507. 48 indexed citations

14.

Koren‐Michowitz, Maya, Elena Ribakovsky, Michaela Schwarz, et al.. (2013). OCT1 genetic variants are associated with long term outcomes in imatinib treated chronic myeloid leukemia patients. European Journal Of Haematology. 92(4). 283–288. 33 indexed citations

15.

Beider, Katia, Elena Ribakovsky, Michal Abraham, et al.. (2011). CXCR4 Antagonist BKT140 Synergizes with Rituximab, Targeting Non Hodgkin Lymphoma (NHL) In Vitro and In Vivo in a Xenograft Model with Bone Marrow Involvement. Blood. 118(21). 952–952. 2 indexed citations

16.

Shimoni, Avichai, Izhar Hardan, Noga Shem‐Tov, et al.. (2008). 158: Relapse of Acute Myeloid Leukmia after Allogeneic Stem-Cell Transplantation (SCT) with Myeloablative Conditioning is Associated with Longer Survival than Relapse after Reduced-Intensity Conditioning (RIC). Biology of Blood and Marrow Transplantation. 14(2). 59–60. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact